Literature DB >> 29802933

Dibucaine in Ionic-Gradient Liposomes: Biophysical, Toxicological, and Activity Characterization.

Verônica M Couto1, Maria J Prieto2, Daniela E Igartúa2, Daniela A Feas2, Lígia N M Ribeiro1, Camila M G Silva1, Simone R Castro1, Viviane A Guilherme1, Darlene D Dantzger1, Daisy Machado1, Silvia Del V Alonso2, Eneida de Paula3.   

Abstract

Administration of local anesthetics is one of the most effective pain control techniques for postoperative analgesia. However, anesthetic agents easily diffuse into the injection site, limiting the time of anesthesia. One approach to prolong analgesia is to entrap local anesthetic agents in nanostructured carriers (e.g., liposomes). Here, we report that using an ammonium sulphate gradient was the best strategy to improve the encapsulation (62.6%) of dibucaine (DBC) into liposomes. Light scattering and nanotracking analyses were used to characterize vesicle properties, such as, size, polydispersity, zeta potentials, and number. In vitro kinetic experiments revealed the sustained release of DBC (50% in 7 h) from the liposomes. In addition, in vitro (3T3 cells in culture) and in vivo (zebrafish) toxicity assays revealed that ionic-gradient liposomes were able to reduce DBC cyto/cardiotoxicity and morphological changes in zebrafish larvae. Moreover, the anesthesia time attained after infiltrative administration in mice was longer with encapsulated DBC (27 h) than that with free DBC (11 h), at 320 μM (0.012%), confirming it as a promising long-acting liposome formulation for parenteral drug administration of DBC.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  controlled release/delivery; encapsulation; formulation; injectables; liposomes; stability; toxicity

Mesh:

Substances:

Year:  2018        PMID: 29802933     DOI: 10.1016/j.xphs.2018.05.010

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Antinociceptive effects of bupivacaine and its sulfobutylether-β-cyclodextrin inclusion complex in orofacial pain.

Authors:  Juliana Souza de Freitas Domingues; Silmara Martins Dias Dos Santos; Julia das Neves Rodrigues Ferreira; Bianca Miguel Monti; Darciane Favero Baggio; Wagner Hummig; Erika Ivanna Araya; Eneida de Paula; Juliana Geremias Chichorro; Luiz Eduardo Nunes Ferreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-08-01       Impact factor: 3.195

2.  Sustained Release from Ionic-Gradient Liposomes Significantly Decreases ETIDOCAINE Cytotoxicity.

Authors:  Juliana Damasceno Oliveira; Lígia Nunes de Morais Ribeiro; Gustavo Henrique Rodrigues da Silva; Bruna Renata Casadei; Verônica Muniz Couto; Elizabeth Ferreira Martinez; Eneida de Paula
Journal:  Pharm Res       Date:  2018-10-10       Impact factor: 4.200

3.  Topical anesthetic analgesic therapy using the combination of ropivacaine and dexmedetomidine: hyaluronic acid modified long-acting nanostructured lipid carriers containing a skin penetration enhancer.

Authors:  Yongjian Yang; Dahai Qiu; Yajun Liu; Lei Chao
Journal:  Drug Des Devel Ther       Date:  2019-09-18       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.